journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://www.readbyqxmd.com/read/29164738/secondary-acute-myeloid-leukaemia-in-elderly-patients-patient-s-fitness-criteria-and-eln-prognostic-stratification-can-be-applied-to-guide-treatment-decisions-an-analysis-of-280-patients-by-the-network-rete-ematologica-lombarda-rel
#1
LETTER
Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, Massimo Bernardi, Claudia Basilico, Elisabetta Todisco, Nicola Fracchiolla, Valentina Mancini, Mauro Turrini, Matteo Da Vià, Elisa Sala, Chiara Cattaneo, Marta Petullà, Federico Serana, Andrea Ferrario, Roberto Cairoli, Agostino Cortelezzi, Armando Santoro, Carlo Castagnola, Giuseppe Rossi
No abstract text is available yet for this article.
November 22, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29164674/outcome-of-chronic-lymphocytic-leukemia-patients-who-switched-from-either-ibrutinib-or-idelalisib-to-alternate-kinase-inhibitor-a-retrospective-study-of-the-french-innovative-leukemia-organization-filo
#2
LETTER
Sophie Godet, Caroline Protin, Jehan Dupuis, Caroline Dartigeas, Jean-Noël Bastie, Charles Herbaux, Véronique Leblond, Sophie de Guibert, David Ghez, Annie Brion, Loïc Ysebaert, Alain Delmer, Anne Quinquenel
No abstract text is available yet for this article.
November 22, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29164670/driver-mutations-and-prognosis-in-primary-myelofibrosis-mayo-careggi-mpn-alliance-study-of-1-095-patients
#3
Ayalew Tefferi, Maura Nicolosi, Mythri Mudireddy, Natasha Szuber, Christy M Finke, Terra L Lasho, Curtis A Hanson, Rhett P Ketterling, Animesh Pardanani, Naseema Gangat, Carmela Mannarelli, Tiziana Fanelli, Paola Guglielmelli, Alessandro M Vannucchi
The 2013 discovery of calreticulin (CALR) mutations in myeloproliferative neoplasms was attended by their association with longer survival in primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and type 2/like CALR mutations and detrimental effect from triple-negative mutational status. Among 709 Mayo Clinic patients with PMF, 467 (66%) harbored JAK2, 112 (16%) CALR type 1/like, 24 (3.4%) CALR type 2/like, 38 (5.4%) MPL mutations and 68 (10%) were triple-negative...
November 22, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29164662/laboratory-tests-for-identification-or-exclusion-of-heparin-induced-thrombocytopenia-hit-or-miss
#4
Emmanuel J Favaloro
Heparin induced thrombocytopenia (HIT) is a potentially fatal condition that arises subsequent to formation of antibodies against complexes containing heparin, usually platelet-factor 4-heparin ('anti-PF4-heparin'). Assessment for HIT involves both clinical evaluation and, if indicated, laboratory testing for confirmation or exclusion, typically using an initial immunological assay ('screening'), and only if positive, a secondary functional assay for confirmation. Many different immunological and functional assays have been developed...
November 22, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29164656/intergroup-leap-trial-s1612-a-randomized-phase-2-3-platform-trial-to-test-novel-therapeutics-in-medically-less-fit-older-adults-with-acute-myeloid-leukemia
#5
LETTER
Roland B Walter, Laura C Michaelis, Megan Othus, Geoffrey L Uy, Jerald P Radich, Richard F Little, Sandi Hita, Lalit Saini, James M Foran, Aaron T Gerds, Heidi D Klepin, Annette E Hay, Sarit Assouline, Jeffrey E Lancet, Stephen Couban, Mark R Litzow, Richard M Stone, Harry P Erba
No abstract text is available yet for this article.
November 22, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29150886/ruxolitinib-associated-infections-a-systematic-review-and-meta-analysis
#6
Federico Lussana, Marco Cattaneo, Alessandro Rambaldi, Alessandro Squizzato
Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious complications. We performed a systematic review of the literature with the aim of estimating the risk of infections in patients treated with ruxolitinib. Studies were identified by electronic search of MEDLINE and EMBASE database. Differences in the incidence of infectious events between ruxolitinib and comparison groups were expressed as odds ratios (ORs) and 95% confidence intervals (95% CI). Five phase III randomized clinical trials (RCTs) (3 phase IIIa with their extended phase and 2 phase IIIb), 6 phase IV studies and 28 case reports were included in this systematic review...
November 18, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29150874/sickle-hemoglobin-oxygen-affinity-shifting-strategies-have-unequal-cerebrovascular-risks
#7
Robert P Hebbel, Bo E Hedlund
No abstract text is available yet for this article.
November 18, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29148089/impact-of-gene-mutations-on-treatment-response-and-prognosis-of-acute-myeloid-leukemia-secondary-to-myeloproliferative-neoplasms
#8
G Venton, F Courtier, A Charbonnier, E D'Incan, C Saillard, B Mohty, M J Mozziconacci, D Birnbaum, A Murati, N Vey, J Rey
Acute myeloid leukemias secondary (sAML) to myeloproliferative neoplasms (MPN) have variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of sAML to MPN are difficult to obtain and there is very little scientific literature or prospective trials for determining robust prognostic markers and efficient treatments. We analyzed event-free survival (EFS) and overall survival (OS) of 73 patients with MPN who progressed to sAML, based on their epidemiological characteristics, the preexisting MPN, the different treatments received, the different prognostic groups and the responses achieved according to the ELN, and their mutational status determined by next-generation DNA sequencing (NGS)...
November 17, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29139135/phase-1-study-of-quizartinib-in-combination-with-induction-and-consolidation-chemotherapy-in-patients-with-newly-diagnosed-acute-myeloid-leukemia
#9
Jessica K Altman, James M Foran, Keith W Pratz, Denise Trone, Jorge E Cortes, Martin S Tallman
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline-based induction/consolidation chemotherapy. Quizartinib is a selective and highly potent FLT3 inhibitor that has shown strong single-agent activity in relapsed or refractory (R/R) AML. This phase 1, open-label, sequential group dose-escalation trial (NCT 01390337) is the first evaluating safety and tolerability of quizartinib in combination with SOC chemotherapy in newly diagnosed AML (ndAML)...
November 15, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29134683/ruxolitinib-as-first-line-treatment-in-secondary-hemophagocytic-lymphohistiocytosis-a-single-patient-experience
#10
LETTER
J Slostad, P Hoversten, C L Haddox, K Cisak, J Paludo, A Tefferi
No abstract text is available yet for this article.
November 14, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29134664/a-phase-ii-trial-of-ruxolitinib-in-combination-with-azacytidine-in-myelodysplastic-syndrome-myeloproliferative-neoplasms
#11
Rita Assi, Hagop M Kantarjian, Guillermo Garcia-Manero, Jorge E Cortes, Naveen Pemmaraju, Xuemei Wang, Graciela Nogueras-Gonzalez, Elias Jabbour, Prithviraj Bose, Tapan Kadia, Courtney D Dinardo, Keyur Patel, Carlos Bueso-Ramos, Lingsha Zhou, Sherry Pierce, Romany Gergis, Carla Tuttle, Gautam Borthakur, Zeev Estrov, Rajyalakshmi Luthra, Juliana Hidalgo-Lopez, Srdan Verstovsek, Naval Daver
Ruxolitinib and azacytidine target distinct disease manifestations of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs). Patients with MDS/MPNs initially received ruxolitinib BID (doses based on platelets count), continuously in 28-day cycles for the first 3 cycles. Azacytidine 25 mg/m(2) (Day 1-5) intravenously or subcutaneously was recommended to be added to each cycle starting cycle 4 and could be increased to 75 mg/m(2) (Days 1-5) for disease control. Azacytidine could be started earlier than cycle 4 and/or at higher dose in patients with rapidly proliferative disease or with elevated blasts...
November 14, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29127684/identification-of-ceruloplasmin-as-a-biomarker-of-chronic-kidney-disease-in-urine-of-sickle-cell-disease-patients-by-proteomic-analysis
#12
LETTER
Marina Jerebtsova, Santosh L Saraf, Xionghao Lin, Gillian Lee, Elena Afia Adjei, Namita Kumari, Nowah Afangbedji, Rasha Raslan, Charlee McLean, Victor R Gordeuk, Sergei Nekhai
No abstract text is available yet for this article.
November 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29124783/a-key-role-for-rac-and-pak-signaling-in-neutrophil-extracellular-traps-nets-formation-defines-a-new-potential-therapeutic-target
#13
M Gavillet, K Martinod, R Renella, D D Wagner, D A Williams
NET formation in mice (NETosis) is supported by reactive oxygen species (ROS) production by NADPH oxidase and histone hypercitrullination by peptidylarginine deiminase 4 (PAD4). Rac1 and Rac2, expressed in polymorphonuclear neutrophils (PMNs), regulate the cytoskeleton, cell shape, adhesion and migration and are also essential components of the NADPH oxidase complex. We aimed to explore the role of the Rac signaling pathway including the upstream guanosine exchange factor (GEF) activator, Vav, and a downstream effector, the p21-activated kinase, Pak, on NETosis in PMNs using a previously described flow-cytometry-based assay...
November 10, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29119643/a-phase-i-study-of-lenalidomide-plus-chemotherapy-with-mitoxantrone-etoposide-and-cytarabine-for-the-reinduction-of-patients-with-acute-myeloid-leukemia
#14
Daniel J DeAngelo, Andrew M Brunner, Lillian Werner, David Avigan, Amir T Fathi, Adam S Sperling, Abigail Washington, Dina Stroopinsky, Jacalyn Rosenblatt, Malgorzata McMasters, Katarina Luptakova, Martha Wadleigh, David P Steensma, Gabriela S Hobbs, Eyal C Attar, Philip C Amrein, Benjamin L Ebert, Richard M Stone, Karen K Ballen
Patients with relapsed AML have a poor prognosis and limited responses to standard chemotherapy. Lenalidomide is an immunomodulatory drug that may modulate anti-tumor immunity. We performed a study to evaluate the safety and tolerability of lenalidomide with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory AML. Adult patients with relapsed/refractory AML were eligible for this phase I dose-escalation study. We enrolled 35 patients using a "3 + 3" design, with a 10 patient expansion cohort at the maximum tolerated dose (MTD)...
November 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29119631/safety-and-efficacy-of-early-start-of-iron-chelation-therapy-with-deferiprone-in-young-children-newly-diagnosed-with-transfusion-dependent-thalassemia-a-randomized-controlled-trial
#15
Mohsen Saleh Elalfy, Amira Adly, Hanem Awad, Mohamed Tarif Salam, Vasilios Berdoukas, Fernando Tricta
Iron overload is inevitable in patients who are transfusion dependent. In young children with transfusion-dependent thalassemia (TDT), current practice is to delay the start of iron chelation therapy due to concerns over toxicities, which have been observed when deferoxamine was started too early. However, doing so may increase the risk of iron accumulation that will be manifested as toxicities later in life. This study investigated whether deferiprone, a chelator with a lower affinity for iron than deferoxamine, could postpone transfusional iron overload while maintaining a good safety profile...
November 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29119605/the-risk-of-venous-thromboembolism-in-patients-with-clinically-overt-gastrointestinal-bleeding
#16
LETTER
Mohammed Almakadi, Christopher Sheasgreen, Ahmed Barefah, Lucy Lu, Nidhi Kumar Tyagi, Gillian Mazzetti, Lindsay Crabbe, Yuhong Yuan, Mark Crowther, Grigorios Leontiadis
No abstract text is available yet for this article.
November 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29119597/hispanic-ethnicity-as-a-risk-factor-for-requiring-glucarpidase-rescue-in-pediatric-patients-receiving-high-dose-methotrexate
#17
LETTER
Eric S Schafer, M Brooke Bernhardt, Kate E Reichert, Tara E Haworth, Mona D Shah
No abstract text is available yet for this article.
November 9, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29114948/excess-mortality-among-ten-year-survivors-of-classical-hodgkin-lymphoma-in-adolescents-and-young-adults
#18
Ana C Xavier, Narendranath Epperla, Jeffrey W Taub, Luciano J Costa
Adolescents and young adults (AYA) surviving classical Hodgkin lymphoma (cHL) risk long term treatment-related toxicity that may be fatal. Although changes in therapy have improved short term toxicity, the subsequent impact on risk of death in survivors is less characterized. We utilized the Surveillance, Epidemiology and End Results (SEER) program to compare excess mortality rate (EMR- observed minus expected mortality) for 10-year survivors of AYA cHL diagnosed in 1973-1992 and 1993-2003 eras. The 15-year EMR reduced from 4...
November 8, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29114918/donor-age-determines-outcome-in-acute-leukemia-patients-over-40-undergoing-haploidentical-hematopoietic-cell-transplantation
#19
Jonathan Canaani, Bipin N Savani, Myriam Labopin, Xiao-Jun Huang, Fabio Ciceri, William Arcese, Yener Koc, Johanna Tischer, Didier Blaise, Zafer Gülbas, Maria Teresa Van Lint, Benedetto Bruno, Mohamad Mohty, Arnon Nagler
Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or matched unrelated donors are unavailable. As several potential haploidentical relative donors are typically available for a given patient, optimizing donor selection to improve clinical outcome is crucial. The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly established in this setting. Using the multinational registry of the acute leukemia working party of the European society for blood and marrow transplantation we retrospective analyzed the clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who underwent haplo-HCT between 2005 and 2015...
November 8, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29098721/comparison-between-the-cll-ipi-and-the-barcelona-brno-prognostic-model-analysis-of-1299-newly-diagnosed-cases
#20
LETTER
Massimo Gentile, Tait D Shanafelt, Francesca R Mauro, Luca Laurenti, Davide Rossi, Stefano Molica, Iolanda Vincelli, Giovanna Cutrona, Giuseppina Uccello, Sara Pepe, Ernesto Vigna, Giovanni Tripepi, Kari G Chaffee, Sameer A Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito
No abstract text is available yet for this article.
November 3, 2017: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"